Detravenol, 1000 mg 18 pcs

Pharmacotherapeutic group: venotonic and venoprotective agent.

ATC code: C05CA53

Pharmacological properties
Pharmacodynamics
The drug is a purified micronized flavonoid fraction consisting of diosmin and other flavonoids converted into hesperidin. This combination has venotonic and angioprotective properties. It reduces venous distensibility and venous stasis, in the microcirculation – reduces capillary permeability and increases their resistance, improves indices of venous hemodynamics. It affects the following venous plethysmographic parameters: venous capacity, venous distensibility, time of venous emptying. The optimal effect is achieved when taking 1000 mg. The drug increases venous tone by reducing the time of venous emptying. In patients with signs of a pronounced microcirculatory disturbance an increase of capillary resistance is noted.
The effectiveness of the drug with respect to indicators of venous hemodynamics in the treatment of chronic diseases of the lower limbs veins and in the treatment of hemorrhoids is demonstrated.

Pharmacokinetics
Half-life is 11 hours.
The drug is actively metabolized, which is confirmed by the presence of phenolic acids in urine. It is excreted mainly through the intestine. The kidneys on average excrete about 14% of the taken dose of the drug.

Indications

Treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:

pain;
spasms of the lower extremities;
feeling of heaviness and fullness in the legs;
“tired” legs.

Treatment of manifestations of venous-lymphatic insufficiency:

swelling of the lower extremities;
trophic changes in the skin and subcutaneous tissue;
venous trophic ulcers.

Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

Pharmacotherapeutic group: venotonic and venoprotective agent.

ATX code: C05CA53

Pharmacological properties
Pharmacodynamics
The drug is a purified micronized flavonoid fraction consisting of diosmin and other flavonoids calculated as hesperidin. This combination has venotonic and angioprotective properties. Reduces the distensibility of veins and venous stagnation, in microcirculation – reduces capillary permeability and increases their resistance, improves venous hemodynamics. It affects the following venous plethysmographic parameters: venous capacity, venous distensibility, time of venous emptying. The optimal effect is achieved when taking 1000 mg. The drug increases venous tone by reducing the time of venous emptying. In patients with signs of severe microcirculation disorders, there is an increase in capillary resistance.
The effectiveness of the drug in relation to venous hemodynamics in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids, has been demonstrated.

Pharmacokinetics
The half-life is 11 hours.
The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine. It is excreted primarily through the intestines. On average, about 14% of the dose taken is excreted by the kidneys.

Special instructions

Before you start taking Detravenol®, it is recommended to consult your doctor.

In case of exacerbation of hemorrhoids, the prescription of Detravenol® does not replace the specific treatment of other anal disorders.

The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings help improve blood circulation.

If there is no improvement or if the symptoms of the disease worsen, consult a doctor!

Do not exceed the maximum duration and recommended doses of the drug without consulting your doctor!

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

Active ingredient: purified micronized flavonoid fraction – 1000,000 mg, including: diosmin (90%) – 900,000 mg; flavonoids in terms of hesperidin (10%) – 100,000 mg.
Excipients: microcrystalline cellulose (MCC-101) – up to 1300,000 mg, sodium carboxymethyl starch – 54,000 mg, gelatin – 46,000 mg, magnesium stearate – 13,000 mg.
Shell composition: opadry II 85F240012 Pink – 40,000 mg, including: polyvinyl alcohol – 16,000 mg, macrogol 3350 – 9,752 mg, titanium dioxide – 8,080 mg, talc – 5,920 mg, iron dye red oxide – 0.160 mg, iron dye yellow oxide – 0.088 mg.

Pregnancy

Pregnancy

Experiments on animals did not reveal teratogenic effects.

To date, there have been no reports of adverse reactions when using the drug by pregnant women.

Breastfeeding period

Due to the lack of data regarding the penetration of the drug into breast milk, women are not recommended to take the drug during breastfeeding.

Effect on reproductive function

Reproductive toxicity studies showed no effect on reproductive function in rats of either sex.

Contraindications

Hypersensitivity to the components of the drug;
Breastfeeding period (experience of use is limited).

Side Effects

The frequency of side effects is determined in accordance with the WHO classification of adverse drug reactions by frequency of occurrence: very often – more than 1/10, often – more than 1/100 and less than 1/10, infrequently – more than 1/1000 and less than 1/100, rarely – more than 1/10000 and less than 1/1000, very rarely – less than 1/10000, including isolated cases; unknown frequency (it is impossible to determine the frequency of occurrence of an adverse reaction based on the available data).

Nervous system disorders: rarely – headache, dizziness, general malaise.

Gastrointestinal disorders: often – diarrhea, dyspepsia, nausea, vomiting; uncommon – colitis; unspecified frequency – abdominal pain.

Disorders of the skin and subcutaneous fat: rarely – skin rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema (Quincke’s edema).

If you experience the side effects listed in the instructions, or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

To date, no cases of drug interactions have been reported.

Overdose

Cases of overdose have not been described.
In case of overdose of the drug, seek medical help immediately!

Storage conditions

At a temperature not higher than 25 ºС.
Keep out of the reach of children.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Ozon, Russia